Fabtech Technologies Limited has informed the Exchange about Investor Presentation
FABTECH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fabtech Technologies shared its investor presentation ahead of the CVOCA Investocraft 2026 conference. The company positions itself as a life sciences infrastructure platform focused on pharma, biotech, and vaccine facilities across GCC, Middle East, and Africa. It estimates the total addressable pharma infrastructure market at USD 115–140 Billion (₹9.5–11.5 Lakh Crore) over 2025–2040. As of January 31, 2026, confirmed orders stood at approximately ₹926 Crore. The company has highlighted a 15-year structural opportunity, references from projects in Saudi Arabia, UAE, and Egypt, and a goal to double its conversion rate from 10% to 20% following its European entity acquisition.
Investors get fresh visibility into Fabtech's growth narrative, order book size, and long-term TAM, which could support sentiment in the near term. However, the presentation is largely strategic and forward-looking, so actual financial performance and execution against the 15-year pipeline will be the key driver of stock price action.